The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes I understand that C19 has likely impacted plans and perhaps delayed anticipated news. Cash from latest raise needed to see through to 2021. Sensible.
Lack of volume and no updates causing SP wobbles but seem to be temporary so far at least. Need to hold above 14p. Moves up on just a few buys....
One decent RNS and I’m sure the SP will rocket into 20s.
Like every business who understands what COVID is bringing - its to strengthen the Balance sheet - i.e give them breathing space... nothing more and nothing less.
The net proceeds of the Placing will be used to further strengthen its balance sheet as partnering and strategic collaborations progress, and to support working capital during the progression of its pipeline portfolio. The net proceeds of the Placing are expected to provide the Company with at least twelve months working capital. The Company's assumptions with regards to its working capital assume that a material tax credit will be received both this year and in H1 2021, as has been the case in previous years.
Back in October2019 shortly after the previous cash raise (!), Clive Dix said:''It's a bargain for anyone who knows and understands the healthcare sector well''.''For people that don't they may get shocked that it takes time, but if you're a slightly longer term investor who understands the healthcare space this is one of the best companies to invest in''.''I've been in this business a long time and I look at all the others ... I put my money behind this and have on a regular basis''.Nearly 7 months on and another raise. Be nice to get a positive update on those commercial deals this week, please Clive.
Compared to most aim entities the placing didnt really do that much damage to the SP. The over subscription if anything shows confidence that decent returns are not far away. Pre placing there were target prices floating around of 30p+ which IMO is still achievable within a month or two.
Taking just over 5% of the company. Positive.
so they raised 1.6 million before expenses,they were looking for a min of a million, so that is a big positive that institutions wanted more at placing price.i think we are in a far stronger position now with regarding negotiating licencing deals with funding in bank to cover next 12 months of research and product development.
I'm hoping they have tapped up a few II's at the 15p on the basis they will be delivering decent news in the next couple of months (if not sooner).
As already highlighted the placing has arrived a little sooner than expected so let's hope they make good use of it and return some actual shareholder value.
lets wait and see the take up of the placing by institutions. just over 6 mths on from last placing that really shafted existing shares holders, By the very nature of this type of company they will burn through cash as its all research based ,the new investors and existing will be fully aware of future pipeline of products and potential timeframe and will act accordingly .
Additional fire power to action strategy. 15p with new shareholder interest. Onwards and upwards.
but true to nature there is the placing, albeit only a million. That wont last very long, really on tax credits. financially this company is a mess.
Rabid, how right you are. And so it came to pass.
Lets hope it heads for 25p fairly soon. Its a little depressing watching the SP fall to this level for no good reason.
Plenty of news in the pipeline so that should help out.
Can see this testing 25p
Not many shares about
SP shows signs of life since the drop in October and reaches a little over 20p only to slump back to 13-14p range.
In the meantime most Pharma shares (including the ones that have nothing to do with Covid19) are flying.
I must be missing something but C4XD seems to have slipped under the radar in a big way.
This peanut allergy is being treated with the drip drip drip of yearly placings. You will get used to this, the BoD certainly have. There will be another in the coming months. Cash burn is horrendous. Great potential but not enough end result.
Just bought some C4XD shares, I don't see why this hasn't peeked when every other pharmaceutical company has. Which is great for me, because I can hopefully get on the act.
Volume picking up. Gap to 40p but can see this much higher
Is this company actually going to deliver is the question? Having just listened to the Proactive interview, it is much the same as the one given 6 months ago just after the huge discounted placing! All jam tomorrow. Also this recent jump to the 20's is the first time the 15p placing holders have had a chance to offload at a profit. May account for the subsequent rapid fall. Frankly they seem to be a long way off from 'Creating the world's most productive drug discovery engine'!!!
Its quite annoying watching Pharma shares getting hyped to the stars on little other than rumour while C4X sit quietly on the sidelines with a whopping number of irons in the fire.
How long will it take investors to realise the value (potentially 10 times more than the current SP)
I hope this goes lower guys. Don't look at the small game, look at the bigger picture. If you can get x10 shares for £1, do it!
This will be worth a fortune one day, it's like a fine wine, stock up now and in 5years you'll be wealthy.
It's like Burford, Fevr etc....
I am allergic to the fact that this excellent, early stage, drug discovery business is valued at peanuts.
I watched the proactive interview & was very encouraged. Active programmes number 6 or 7 and it is clear that there is novel science behind each & that each are intended to meet clinical needs for which there is large demand. IE: none of them are vanity projects.
Both the sickle-cell & psoriasis programmes look like major potential licensing opportunities, ie somewhere north in value of the Indivior deal.
Patience may be required but here, i suspect, patience will indeed be a virtue.
Our business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, we successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.
Seems there model us based on the licensing deals Trevor...I know so far they have only received 10 million from the indivior deal. Mostly acquiring deals and partnerships with various developers
Some big delayed trades there...yep one sell but definitely some premium price buys too
Slightly disappointing day given the RNS was pretty rock solid with no nasty surprises. Hopefully a bit more news in the very near future will give the uplift many were expecting.
Holding up pre news limit now...watch if LifeArc make announcement this begin to become very busy again. Nothing wrong with results and perhaps people buying and selling on the quick rise yesterday